About Purposeful
Purposeful is a company based in Athens (Greece) founded in 2000. It operates as a AI-as-a-Service and Professional Services. Purposeful has raised $293.9 thousand across 2 funding rounds from investors including PharOS and Metavallon. Purposeful offers products and services including Drug Repurposing for Rare Diseases and AI-Driven Drug Discovery. Purposeful operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Athens, Greece
- SectorsHealthcare
- Phone•••• ••••
- Website purposeful.eu
- Social LinkedIn X Facebook
- Total Equity Funding$293.9K (USD)
in 2 rounds
- InvestorsPharOS
& 1 more
Products & Services of Purposeful
Purposeful offers a comprehensive portfolio of products and services, including Drug Repurposing for Rare Diseases and AI-Driven Drug Discovery.
Drugs are repurposed to treat rare genetic disorders.
AI is utilized to rediscover drugs for diseases.
Funding Insights of Purposeful
Purposeful has successfully raised a total of $293.9K across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $293,896
- Total Rounds 2
- First Round $293,896
(Sep 2018)
- Investors Count 2
All 2 funding rounds of Purposeful with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | – | Seed | – | PharOS | – |
| Sep 2018 | $293,896 | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Purposeful
Purposeful has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include PharOS and Metavallon.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC firm and startup accelerator | – | metavallon.vc | Athens, Greece | |
Generic drugs are manufactured and supplied by PharOS. | 2002 | pharosgr.gr | Metamorfosi, Greece |
Investor details for Purposeful
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Purposeful
3 dated milestones of Purposeful across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Purposeful is founded.
- Funding First funding round of $294K.
- Funding Latest funding round, Seed,.
Competitors of Purposeful
Purposeful operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| sanofigenzyme.com | 1981 | Cambridge, United States | – | – | Antibody-drug conjugates are developed for treating multiple diseases. | |
| amicusrx.com | 2002 | Philadelphia, United States | $91M | 517 | Developer of therapies for rare and orphan diseases |
Detailed competitors of Purposeful
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Purposeful
The website of Purposeful (purposeful.eu) receives about 1.6K visits a month.
- Monthly visits1.6K
▼ 32.5% vs previous month
Similar companies to Purposeful
10 companies that operate in the same segment as Purposeful (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Purposeful
Purposeful was founded in 2000 and raised its 1st funding round 18 years after it was founded.
Purposeful is headquartered in Athens, Greece.
Purposeful is a funded company, having raised a total of $293.9K across 2 funding rounds to date. The company's 1st funding round was a Seed of $293.9K, raised on Sep 2018.
Purposeful is focused on discovering new treatments and developing pharmaceutical products for rare diseases by repurposing already marketed drugs. The company employs AI-driven approaches to revisit both rare and common diseases, aiming to reverse disease phenotypes. Collaborations with organizations like FRAXA, BIOEMTECH, and Leo Pharma Ltd are maintained to identify and validate drug repurposing candidates across various conditions such as Fragile X Syndrome, Glioblastoma, and dermatology indications. The healthcare sector, particularly rare disease treatment, is the primary area of operation.
Purposeful's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Purposeful offers Drug Repurposing for Rare Diseases and AI-Driven Drug Discovery.
Purposeful has 2 investors. Key investors include PharOS, and Metavallon.